Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. [construction And Evaluation Of A Prognostic Risk Prediction Model Of Pancreatic Ductal Adenocarcinoma Based On Immune-related Genes]

[Construction and Evaluation of a Prognostic Risk Prediction Model of Pancreatic Ductal Adenocarcinoma Based on Immune-Related Genes]

Yu Zhang1, Rui-Ping Ren1, Peng Wan1

  • 1Cancer Radiotherapy and Chemotherapy Center,The Affiliated People's Hospital of Ningbo University,Ningbo,Zhejiang 315040,China.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|July 2, 2024

Related Experiment Videos

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.1K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed an Integrated Immune Score (IIS) to predict pancreatic ductal adenocarcinoma (PDAC) patient outcomes. The IIS effectively stratified patients into high-risk and low-risk groups, aiding in prognosis.

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis.
  • Identifying reliable prognostic markers is crucial for effective patient management.

Purpose of the Study:

  • To develop a risk prediction model for PDAC by integrating molecular subtypes and immune-related genes.
  • To establish an Integrated Immune Score (IIS) for prognostic assessment.

Main Methods:

  • Differential gene expression analysis between PDAC subtypes (squamous vs. non-squamous) using GSE71729 dataset.
  • Construction of a gene regulatory network to identify five key immune marker genes.
  • Development and validation of the IIS model using survival data from training and validation sets.
Keywords:
immune-related genepancreatic ductal adenocarcinomaprognosis

Related Experiment Videos

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.3K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.1K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Main Results:

  • The IIS model stratified PDAC patients into high-risk and low-risk groups.
  • Patients in the high-risk group exhibited significantly shorter overall survival in both training and validation cohorts (P<0.001).
  • Multivariable Cox regression confirmed IIS as an independent prognostic factor for PDAC (HR=2.16, P<0.001).

Conclusions:

  • The Integrated Immune Score (IIS) demonstrates robust predictive performance for PDAC patient prognosis.
  • IIS can serve as a valuable tool for risk stratification in PDAC.
  • IIS holds potential as a novel prognostic biomarker for pancreatic ductal adenocarcinoma.